SPDR S&P Pharmaceuticals ETF (XPH)
NYSEArca - NYSEArca Delayed Price. Currency in USD
- Market Realist•14 days ago
Oncology is the first area of focus for Bristol-Myers Squibb (BMY). Along with Opdivo and Yervoy, BMY’s oncology franchise includes Empliciti (elotuzumab) and Sprycel (dasatinib).
- Market Realist•16 days ago
CheckMate-141 Bristol-Myers Squibb’s (BMY) CheckMate-141 evaluated Opdivo for the treatment of squamous cell carcinoma of the head and neck. The study was stopped after meeting the primary endpoint in ...